CD300家族及其调控免疫细胞抗肿瘤作用机制的研究进展

doi:10.3760/cma.j.cn371439-20251106-00048

国际肿瘤学杂志 ›› 2026, Vol. 53 ›› Issue (5): 296-300.doi: 10.3760/cma.j.cn371439-20251106-00048

CD300家族及其调控免疫细胞抗肿瘤作用机制的研究进展

于欣静, 杨阳, 李殊瑶, 乔晓娟()

内蒙古医科大学附属医院肿瘤内科，呼和浩特 010050

收稿日期:2025-11-06 出版日期:2026-05-08 发布日期:2026-05-06
通讯作者: 乔晓娟，Email： xiaojuanqiao@126.com
基金资助:
内蒙古自治区自然科学基金(2021MS08153);内蒙古自治区高校青年科技英才项目(NJYT22011);内蒙古自治区高等学校科学研究项目(NJZY21596);内蒙古自治区卫生健康科技计划(202201295);内蒙古医科大学“科技百万工程”［YKD2020KJBW（LH）039］;内蒙古医科大学“致远”人才计划“善学”人才项目(ZY0202022);内蒙古医学科学院公立医院科研联合基金科技项目(2024GLLH0311)

Research progress on the CD300 family and its mechanism of regulating the anti-tumor effects of immune cells

Yu Xinjing, Yang Yang, Li Shuyao, Qiao Xiaojuan()

Department of Medical Oncology， Affiliated Hospital of Inner Mongolia Medical University， Hohhot 010050， China

Received:2025-11-06 Online:2026-05-08 Published:2026-05-06
Supported by:
Natural Science Foundation of Inner Mongolia Autonomous Region(2021MS08153);2022 Youth Science and Technology Talents of Higher Education Institutions of Inner Mongolia Autonomous Region(NJYT22011);Scientific Research Project of Higher Education Institutions of Inner Mongolia Autonomous Region(NJZY21596);Health Science and Technology Project of Inner Mongolia Autonomous Region(202201295);"Science and Technology Million Joint Project" of Inner Mongolia Medical University [YKD2020KJBW （LH） 039];"Shanxue" Talents of "Zhiyuan" Talent Program of Inner Mongolia Medical University(ZY0202022);Science and Technology Program of the Joint Fund of Scientific Research for the Public Hospitals of Inner Mongolia Academy of Medical Sciences(2024GLLH0311)

摘要/Abstract

摘要：

CD300家族作为免疫球蛋白（Ig）超家族的重要成员，具有保守的Ig结构域和多样化的胞内信号基序，广泛存在于各类免疫细胞及肿瘤细胞中，因不同亚型结构组成存在差异，该家族成员分化为抑制性或激活性受体，表现出功能的异质性，在肿瘤免疫微环境中扮演双重角色，既可促进免疫激活，也可介导免疫抑制。在肿瘤免疫微环境中直接或间接调控髓系细胞（巨噬细胞、树突状细胞、多形核样的髓系来源抑制性细胞）与淋巴细胞（自然杀伤细胞、T细胞）的功能，成为肿瘤免疫逃逸的关键节点。从CD300家族调节免疫细胞发挥抗肿瘤作用出发，对其生物学功能及其与肿瘤发生发展的相关性进行综述，可为肿瘤免疫治疗及耐药提供新的研究思路。

关键词: 免疫球蛋白类, 肿瘤, 肿瘤微环境, CD300家族

Abstract:

As an important member of the immunoglobulin （Ig） superfamily， the CD300 family possesses conserved Ig domains and diverse intracellular signaling motifs， and is widely present in various immune cells and tumor cells. Due to differences in the structural composition of different subtypes， members of this family are classified into inhibitory or activating receptors， exhibiting functional heterogeneity. They play a dual role in the tumor immune microenvironment： they can either promote immune activation or mediate immune suppression. By directly or indirectly regulating the functions of myeloid cells （macrophages， dendritic cells， polymorphonuclear-like myeloid-derived suppressor cells） and lymphocytes （natural killer cells， T cells） in the tumor immune microenvironment， the CD300 family serves as a key node in tumor immune escape. Based on the anti-tumor effect of CD300 family regulating immune cells， this article reviews the biological functions of CD300 family and its correlation with tumor occurrence and development， which can provide new research ideas for tumor immunotherapy and drug resistance.

Key words: Immunoglobulins, Neoplasms, Tumor microenvironment, CD300 family

于欣静, 杨阳, 李殊瑶, 乔晓娟. CD300家族及其调控免疫细胞抗肿瘤作用机制的研究进展[J]. 国际肿瘤学杂志, 2026, 53(5): 296-300.

Yu Xinjing, Yang Yang, Li Shuyao, Qiao Xiaojuan. Research progress on the CD300 family and its mechanism of regulating the anti-tumor effects of immune cells[J]. Journal of International Oncology, 2026, 53(5): 296-300.

参考文献 45

[1]	Borrego F. The CD300 molecules: an emerging family of regulators of the immune system[J]. Blood, 2013, 121(11): 1951-1960. DOI: 10.1182/blood-2012-09-435057. pmid: 23293083
[2]	Valiate BVS, Alvarez RU, Karra L, et al. The immunoreceptor CD300a controls the intensity of inflammation and dysfunction in a model of Ag-induced arthritis in mice[J]. J Leukoc Biol, 2019, 106(4): 957-966. DOI: 10.1002/JLB.3A1018-389R.
[3]	Munitz A, Bachelet I, Eliashar R, et al. The inhibitory receptor IRp60 (CD300a) suppresses the effects of IL-5, GM-CSF, and eotaxin on human peripheral blood eosinophils[J]. Blood, 2006, 107(5): 1996-2003. DOI: 10.1182/blood-2005-07-2926. pmid: 16254138
[4]	Cantoni C, Bottino C, Augugliaro R, et al. Molecular and functional characterization of IRp60, a member of the immunoglobulin superfamily that functions as an inhibitory receptor in human NK cells[J]. Eur J Immunol, 1999, 29(10): 3148-3159. DOI: 10.1002/(SICI)1521-4141(199910)29:10<3148::AID-IMMU3148>3.0.CO;2-L.
[5]	Vitallé J, Terrén I, Orrantia A, et al. CD300 receptor family in viral infections[J]. Eur J Immunol, 2019, 49(3): 364-374. DOI: 10.1002/eji.201847951. pmid: 30485414
[6]	Niizuma K, Tahara-Hanaoka S, Noguchi E, et al. Identification and characterization of CD300H, a new member of the human CD300 immunoreceptor family[J]. J Biol Chem, 2015, 290(36): 22298-22308. DOI: 10.1074/jbc.M115.643361. pmid: 26221034
[7]	Lee SI, Kim H, Lim CK, et al. Engagement of CD300c by a novel monoclonal antibody induces the differentiation of monocytes to M1 macrophages[J]. Immunobiology, 2024, 229(1): 152780. DOI: 10.1016/j.imbio.2023.152780.
[8]	Vitallé J, Terrén I, Orrantia A, et al. The Expression and function of CD300 molecules in the main players of allergic responses: mast cells, basophils and eosinophils[J]. Int J Mol Sci, 2020, 21(9): 3173. DOI: 10.3390/ijms21093173.
[9]	Zenarruzabeitia O, Astarloa-Pando G, Terrén I, et al. T cell activation, highly armed cytotoxic cells and a shift in monocytes cd300 receptors expression is characteristic of patients with severe COVID-19[J]. Front Immunol, 2021, 12: 655934. DOI: 10.3389/fimmu.2021.655934.
[10]	Evans F, Alí-Ruiz D, Rego N, et al. CD300f immune receptor contributes to healthy aging by regulating inflammaging, metabolism, and cognitive decline[J]. Cell Rep, 2023, 42(10): 113269. DOI: 10.1016/j.celrep.2023.113269.
[11]	Zelenka L, Jarek M, Pägelow D, et al. Crosstalk of highly purified microglia and astrocytes in the frame of toll-like receptor (TLR)2/1 activation[J]. Neuroscience, 2023, 526: 256-266. DOI: 10.1016/j.neuroscience.2023.05.001.
[12]	Lindblad C, Klang A, Bark D, et al. Influence of apolipoprotein E genotype on the proteomic profile in cerebral microdialysis after human severe traumatic brain injury: a prospective observational study[J]. Brain Commun, 2025, 7(2): fcaf096. DOI: 10.1093/braincomms/fcaf096.
[13]	Nakahashi-Oda C, Tahara-Hanaoka S, Shoji M, et al. Apoptotic cells suppress mast cell inflammatory responses via the CD300a immunoreceptor[J]. J Exp Med, 2012, 209(8): 1493-1503. DOI: 10.1084/jem.20120096.
[14]	Dimitrova M, Zenarruzabeitia O, Borrego F, et al. CD300c is uniquely expressed on CD56 bright natural killer cells and differs from CD300a upon ligand recognition[J]. Sci Rep, 2016, 6: 23942. DOI: 10.1038/srep23942. pmid: 27040328
[15]	Lee H, Nakahashi-Oda C, Lyu W, et al. Inhibitory immunoreceptors CD300a and CD300lf cooperate to regulate mast cell activation[J]. J Immunol, 2025, 214(3): 325-334. DOI: 10.1093/jimmun/vkae030. pmid: 40073110
[16]	Yang T, Zhang Y, Duan CJ, et al. CD300E⁺ macrophages facilitate liver regeneration after splenectomy in decompensated cirrhotic patients[J]. Exp Mol Med, 2025, 57(1): 72-85. DOI: 10.1038/s12276-024-01371-3. pmid: 39741181
[17]	Dias C, Levi-Schaffer F, Esteves PJ. Evolutionary analysis of CD300A and CD300C paired receptors in primates[J]. Front Immunol, 2025, 16: 1633323. DOI: 10.3389/fimmu.2025.1633323.
[18]	Negro-Demontel L, Evans F, Cawen FA, et al. CD300f enables microglial damage sensing, efferocytosis, and apoptotic cell metabolization after brain injury[J]. Brain Behav Immun, 2025, 130: 106105. DOI: 10.1016/j.bbi.2025.106105.
[19]	Tamene W, Abebe M, Wassie L, et al. PDL1 expression on monocytes is associated with plasma cytokines in Tuberculosis and HIV[J]. PLoS One, 2021, 16(10): e0258122. DOI: 10.1371/journal.pone.0258122.
[20]	Kavianpour AA, Ghasempour S, Meyer KJ, et al. Phosphatidylethanolamine is a phagocytic ligand implicated in the binding and removal of apoptotic and bacterial extracellular vesicles[J]. Curr Biol, 2025, 35(17): 4276-4284.e5. DOI: 10.1016/j.cub.2025.07.043.
[21]	Wang CX, Zheng XC, Zhang JL, et al. CD300ld on neutrophils is required for tumour-driven immune suppression[J]. Nature, 2023, 621(7980): 830-839. DOI: 10.1038/s41586-023-06511-9.
[22]	Wen XM, Xu ZJ, Ma JC, et al. Bioinformatic characterization of STING expression in hematological malignancies reveals association with prognosis and anti-tumor immunity[J]. Front Immunol, 2025, 16: 1477100. DOI: 10.3389/fimmu.2025.1477100.
[23]	Kawai T, Ikegawa M, Ori D, et al. Decoding Toll-like receptors: recent insights and perspectives in innate immunity[J]. Immunity, 2024, 57(4): 649-673. DOI: 10.1016/j.immuni.2024.03.004. pmid: 38599164
[24]	Demaria O, Cornen S, Daëron M, et al. Harnessing innate immunity in cancer therapy[J]. Nature, 2019, 574(7776): 45-56. DOI: 10.1038/s41586-019-1593-5.
[25]	Rothlin CV, Ghosh S. Lifting the innate immune barriers to antitumor immunity[J]. J Immunother Cancer, 2020, 8(1): e000695. DOI: 10.1136/jitc-2020-000695.
[26]	Yao J, Ji LL, Wang G, et al. Effect of neutrophils on tumor immunity and immunotherapy resistance with underlying mechanisms[J]. Cancer Commun (Lond), 2025, 45(1): 15-42. DOI: 10.1002/cac2.12613.
[27]	Peng JM, Liu HY. CD300a: an innate immune checkpoint shaping tumor immunity and therapeutic opportunity[J]. Cancers (Basel), 2025, 17(11): 1786. DOI: 10.3390/cancers17111786.
[28]	Tian L, Choi SC, Lee HN, et al. Enhanced efferocytosis by dendritic cells underlies memory T-cell expansion and susceptibility to auto-immune disease in CD300f-deficient mice[J]. Cell Death Differ, 2016, 23(6): 1086-1096. DOI: 10.1038/cdd.2015.161. pmid: 26768664
[29]	Murakami Y, Tian L, Voss OH, et al. CD300b regulates the phagocytosis of apoptotic cells via phosphatidylserine recognition[J]. Cell Death Differ, 2014, 21(11): 1746-1757. DOI: 10.1038/cdd.2014.86. pmid: 25034781
[30]	Voss OH, Tian LJ, Murakami Y, et al. Emerging role of CD300 receptors in regulating myeloid cell efferocytosis[J]. Mol Cell Oncol, 2015, 2(4): e964625. DOI: 10.4161/23723548.2014.964625.
[31]	Nakahashi-Oda C, Udayanga KG, Nakamura Y, et al. Apoptotic epithelial cells control the abundance of treg cells at barrier surfaces[J]. Nat Immunol, 2016, 17(4): 441-450. DOI: 10.1038/ni.3345. pmid: 26855029
[32]	Voss OH, Murakami Y, Pena MY, et al. Lipopolysaccharide-induced CD300b receptor binding to Toll-like receptor 4 alters signaling to drive cytokine responses that enhance septic shock[J]. Immunity, 2016, 44(6): 1365-1378. DOI: 10.1016/j.immuni.2016.05.005. pmid: 27261276
[33]	Moshkovits I, Karo-Atar D, Itan M, et al. CD300f associates with IL-4 receptor α and amplifies IL-4-induced immune cell responses[J]. Proc Natl Acad Sci U S A, 2015, 112(28): 8708-8713. DOI: 10.1073/pnas.1507625112.
[34]	Carroll SL, Pasare C, Barton GM. Control of adaptive immunity by pattern recognition receptors[J]. Immunity, 2024, 57(4): 632-648. DOI: 10.1016/j.immuni.2024.03.014. pmid: 38599163
[35]	Zhang SQ, Thomas F, Fang J, et al. Universal protection of allogeneic T-cell therapies from natural killer cells via CD300a agonism[J]. Blood Adv, 2025, 9(2): 254-264. DOI: 10.1182/bloodadvances.2024013436.
[36]	Kim EJ, Lee SM, Suk K, et al. CD300a and CD300f differentially regulate the MyD88 and TRIF-mediated TLR signalling pathways through activation of SHP-1 and/or SHP-2 in human monocytic cell lines[J]. Immunology, 2012, 135(3): 226-235. DOI: 10.1111/j.1365-2567.2011.03528.x.
[37]	Sutherland SIM, Ju XS, Silveira PA, et al. CD300f signalling induces inhibitory human monocytes/macrophages[J]. Cell Immunol, 2023, 390: 104731. DOI: 10.1016/j.cellimm.2023.104731.
[38]	Simhadri VR, Mariano JL, Gil-Krzewska A, et al. CD300c is an activating receptor expressed on human monocytes[J]. J Innate Immun, 2013, 5(4): 389-400. DOI: 10.1159/000350523. pmid: 23571507
[39]	Coletta S, Salvi V, Della Bella C, et al. The immune receptor CD300e negatively regulates T cell activation by impairing the STAT1-dependent antigen presentation[J]. Sci Rep, 2020, 10(1): 16501. DOI: 10.1038/s41598-020-73552-9. pmid: 33020563
[40]	Silva R, Moir S, Kardava L, et al. CD300a is expressed on human B cells, modulates BCR-mediated signaling, and its expression is down-regulated in HIV infection[J]. Blood, 2011, 117(22): 5870-5880. DOI: 10.1182/blood-2010-09-310318. pmid: 21482706
[41]	Nakano-Yokomizo T, Tahara-Hanaoka S, Nakahashi-Oda C, et al. The immunoreceptor adapter protein DAP12 suppresses B lymphocyte- driven adaptive immune responses[J]. J Exp Med, 2011, 208(8): 1661-1671. DOI: 10.1084/jem.20101623.
[42]	Du XR, Liu B, Ding Q, et al. CD300A inhibits tumor cell growth by downregulating AKT phosphorylation in human glioblastoma multiforme[J]. Int J Clin Exp Pathol, 2018, 11(7): 3471-3478.
[43]	Sun XG, Huang SH, Wang X, et al. CD300A promotes tumor progression by PECAM1, ADCY7 and AKT pathway in acute myeloid leukemia[J]. Oncotarget, 2018, 9(44): 27574-27584. DOI: 10.18632/oncotarget.24164. pmid: 29938007
[44]	Liu N, Sun WC, Gao WX, et al. CD300e: Emerging role and mechanism as an immune-activating receptor[J]. Int Immunopharmacol, 2024, 133: 112055. DOI: 10.1016/j.intimp.2024.112055.
[45]	Abe F, Nakahashi-Oda C, Lee H, et al. A humanized monoclonal antibody against CD300A ameliorates acute ischemic stroke in humanized mice[J]. Monoclon Antib Immunodiagn Immunother, 2025, 44(1): 2-7. DOI: 10.1089/mab.2024.0027. pmid: 39804190

CD300家族及其调控免疫细胞抗肿瘤作用机制的研究进展

Research progress on the CD300 family and its mechanism of regulating the anti-tumor effects of immune cells

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 45

相关文章 15

编辑推荐

Metrics

本文评价

[1]	钱海洪, 王雪梅, 刘四艳, 王华, 张恒姣, 杨东海, 孙琼, 赵聃冶. IFITM1基因沉默降低小细胞肺癌细胞顺铂耐药性的作用及机制[J]. 国际肿瘤学杂志, 2026, 53(5): 268-275.
[2]	杨松, 郑相云, 潘映雪, 王嘉明, 张焕虎. 伊马替尼辅助治疗对非胃原发高危GIST患者术后预后的影响[J]. 国际肿瘤学杂志, 2026, 53(5): 283-289.
[3]	张状, 王倩, 杨愈佳, 魏海阔, 刘畅. 钆塞酸二钠增强MRI联合DWI成像对肝细胞癌血管包绕肿瘤细胞簇阳性的评估价值[J]. 国际肿瘤学杂志, 2026, 53(5): 290-295.
[4]	李丽娜, 刘帅, 张楠. 乳腺癌术前放疗研究进展[J]. 国际肿瘤学杂志, 2026, 53(5): 301-305.
[5]	李一平, 唐桩, 欧阳苏瑞, 李进, 何敬东. 神经激肽-1受体拮抗剂在肺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2026, 53(5): 306-310.
[6]	赵娟, 余娇凤, 魏澳娇, 戴以雪, 赵艳, 符叶, 赵明利. 肺癌免疫治疗相关心肌炎的研究进展[J]. 国际肿瘤学杂志, 2026, 53(5): 311-316.
[7]	杨宗昌, 徐会, 周福祥. 十二指肠腺癌伴多发转移综合治疗1例并文献复习[J]. 国际肿瘤学杂志, 2026, 53(5): 317-320.
[8]	刘鲁嘉, 王玉坤, 郑海涛. 肠道菌群与甲状腺癌因果关系的研究[J]. 国际肿瘤学杂志, 2026, 53(4): 193-200.
[9]	谢文娟, 朱媛, 许晶. 基于SMOTE算法的食管癌患者术后急性呼吸衰竭风险预测模型构建[J]. 国际肿瘤学杂志, 2026, 53(4): 213-218.
[10]	韩宇飞, 李凤梅, 张维娜, 张萍, 侯萍. 同步放化疗后安罗替尼维持治疗局部晚期宫颈癌的短期疗效与临床观察[J]. 国际肿瘤学杂志, 2026, 53(4): 219-223.
[11]	杨心茹, 曹莉莉. CC及CXC趋化因子在肿瘤微环境中的作用及治疗潜力[J]. 国际肿瘤学杂志, 2026, 53(4): 224-228.
[12]	刘凯, 廖智鹏, 杜爱超, 董志强. 微嵌合体在恶性肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2026, 53(4): 229-233.
[13]	仝心雨, 杨静, 王明磊, 黄承锁, 罗应舒, 彭洁琼, 韩淑梅, 刘波. 食管癌内科治疗的现状与进展[J]. 国际肿瘤学杂志, 2026, 53(4): 240-247.
[14]	李志磊, 方金满, 魏丹丹, 孙瑞霞, 张远伟. 局部晚期中低位直肠癌新辅助放化疗后病理反应的相关研究进展[J]. 国际肿瘤学杂志, 2026, 53(4): 248-252.
[15]	王雨蒙, 辛恺, 田漫漫, 邵洁, 陈文秀, 刘宝瑞, 刘芹. 个体化新抗原疫苗治疗肺腺样囊性癌1例并文献复习[J]. 国际肿瘤学杂志, 2026, 53(4): 253-256.